HRTX Heron Therapeutics Inc.

24.97
-1.09  -4%
Previous Close 26.06
Open 25.94
Price To Book 4.79
Market Cap 1948135204
Shares 78,019,031
Volume 642,083
Short Ratio
Av. Daily Volume 989,853

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced October 31, 2018.
HTX-011
Post operative pain
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
Approval announced November 9, 2017.
CINVANTI (HTX-019)
Prevention of chemotherapy-induced nausea and vomiting (CINV)
Phase 2 data released June 21, 2018. Primary endpoint met.
HTX-011
Total knee arthroplasty

Latest News

  1. Hedge Funds Are Buying Heron Therapeutics Inc (HRTX)
  2. Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals
  3. Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
  4. Today's Research Reports on Trending Tickers: Cronos Group and Heron Therapeutics
  5. When Will Heron Therapeutics Inc (NASDAQ:HRTX) Become Profitable?
  6. Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference
  7. U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics
  8. Today's Research Reports on Trending Tickers: Heron Therapeutics and Bristol-Myers Squibb
  9. Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
  10. Heron Therapeutics: 3Q Earnings Snapshot
  11. Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress
  12. Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
  13. Cramer's lightning round: If you want to invest in non-op...
  14. Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx — New Research Emphasizes Economic Growth
  15. Why Heron Therapeutics Inc (NASDAQ:HRTX) Is A Financially Healthy Company
  16. Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Heron Therapeutics
  17. Heron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
  18. Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options
  19. Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September